Publications by authors named "Qianzhe Zhu"
Integrated Osteoinductive Factors─Exosome@MicroRNA-26a Hydrogel Enhances Bone Regeneration.
ACS Appl Mater Interfaces
May 2023
MicroRNAs (miRNAs) are a new therapeutic tool that can target multiple genes by inducing translation repression and target mRNA degradation. Although miRNAs have gained significant attention in oncology and in work on genetic disorders and autoimmune diseases, their application in tissue regeneration remains hindered by several challenges, such as miRNA degradation. Here, we reported Exosome@MicroRNA-26a (Exo@miR-26a), an osteoinductive factor that can be substituted for routinely used growth factors, which was constructed using bone marrow stem cell (BMSC)-derived exosomes and microRNA-26a (miR-26a).
View Article and Find Full Text PDFTraditional Chinese Medicine Containing Arsenic Treated MDS Patients Effectively through Regulating Aberrant Hypomethylation.
Evid Based Complement Alternat Med
March 2020
Article Synopsis
- Aberrant hypermethylation and hypomethylation are crucial factors in myelodysplastic syndrome (MDS), and while hypomethylating agents show promise, their effectiveness is limited, highlighting the need for new treatments.
- A study involving 135 MDS patients treated with Chinese medicine (CM) for over 36 months showed high response rates: 81.53% for hematological improvement and 80% for bone marrow complete response in specific patient groups.
- Analysis revealed that CM treatment can positively impact gene methylation profiles, increasing the expression of DNMT1 and improving aberrant hypomethylation, thus supporting the potential of CM herbs, particularly those with arsenic, as a novel treatment for MDS
Objective: To investigate the relation of blood arsenic concentration (BAC) with clinical effect and safety of arsenic-containing Qinghuang Powder (, QHP) in patients with myelodysplastic syndrome (MDS).
Methods: Totally 163 patients with MDS were orally treated with QHP for 2 courses of treatment, 3 months as 1 course. The BACs of patients were detected by atomic fluorescence spectrophotometry at 1, 3, and 6 months during the treatment, and the effective rate, hematological improvement and safety in patients after treatment with QHP were analyzed.
Study on the Clinical Safe and Effective Methods of Arsenic-Containing Compound-Qinghuang Powder in the Treatment of Myelodysplastic Syndrome.
Evid Based Complement Alternat Med
November 2017
Objective: To establish the clinical safe and effective methods of arsenic-containing compound-Qinghuang Powder (compound-QHP) in the treatment of myelodysplastic syndrome (MDS).
Methods: 200 patients with MDS were treated with compound-QHP (daily dose of 0.1 g realgar).